Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAZ 10397767
说明： Potent CXCR2 antagonist
化学名： 5-[[(3-Chloro-2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one
纯度： ≥98% (HPLC)
生物活性 for AZ 10397767
AZ 10397767 is a potent CXCR2 antagonist (IC50 = 1 nM); attenuates oxaliplatin-induced NF-κB activation, increases oxaliplatin cytotoxicity, and potentiates oxaliplatin-induced apoptosis in AIPC cells. Reduces the numbers of neutrophils infiltrating into tumors in both in vitro and in vivo models and delayed tumor growth. Orally bioavailable.
化合物库 for AZ 10397767
AZ 10397767 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. 了解 Tocris 化合物库的更多信息。
技术数据 for AZ 10397767
| 分子量 | 400.88 |
| 公式 | C15H14ClFN4O2S2 |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 333742-63-5 |
| PubChem ID | 11858154 |
| InChI Key | KHTUORKUWBDRBX-SSDOTTSWSA-N |
| Smiles | C[C@@H](NC1=C2SC(NC2=NC(SCC3=C(C(Cl)=CC=C3)F)=N1)=O)CO |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for AZ 10397767
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 40.09 | 100 |
制备储备液 for AZ 10397767
以下数据基于产品分子量 400.88。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.49 mL | 12.47 mL | 24.95 mL |
| 5 mM | 0.5 mL | 2.49 mL | 4.99 mL |
| 10 mM | 0.25 mL | 1.25 mL | 2.49 mL |
| 50 mM | 0.05 mL | 0.25 mL | 0.5 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for AZ 10397767
参考文献 for AZ 10397767
参考文献是支持产品生物活性的出版物。
Wilson et al (2008) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxalip. through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J.Pharmacol.Exp.Ther. 327 746 PMID: 18780829
Walters et al (2008) Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg.Med.Chem.Lett. 18 798 PMID: 18240390
Tazzyman et al (2011) Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int.J.Cancer 129 847 PMID: 21328342
If you know of a relevant reference for AZ 10397767, please let us know.
按产品操作查看相关产品
关键词: AZ 10397767, AZ 10397767 supplier, AZ10397767, chemokine, cxc, receptors, antagonists, antagonism, orally, bioavailable, potent, selective, Chemokine, CXC, Receptors, 5872, Tocris Bioscience
篇 AZ 10397767 的引用文献
引用文献是使用了 Tocris 产品的出版物。
目前没有 AZ 10397767 的引用文献。 您是否知道使用了 Tocris AZ 10397767 的优秀论文？ 请告知我们.
AZ 10397767 的评论
目前没有该产品的评论。 Be the first to review AZ 10397767 and earn rewards!
Have you used AZ 10397767?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.